{"id":542767,"date":"2021-05-11T18:40:02","date_gmt":"2021-05-11T18:40:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=542767"},"modified":"2021-05-11T18:40:02","modified_gmt":"2021-05-11T18:40:02","slug":"xerostomia-treatment-market-epidemiology-emerging-therapies-and-key-companies-working-in-the-domain-during-the-study-period-201830-in-the-7mm","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/xerostomia-treatment-market-epidemiology-emerging-therapies-and-key-companies-working-in-the-domain-during-the-study-period-201830-in-the-7mm_542767.html","title":{"rendered":"Xerostomia Treatment Market, Epidemiology, Emerging Therapies and Key Companies Working in the Domain During the Study Period (2018-30) in the 7MM"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1620713382.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Xerostomia Treatment Market, Epidemiology, Emerging Therapies and Key Companies Working in the Domain During the Study Period (2018-30) in the 7MM\" src=\"https:\/\/www.abnewswire.com\/uploads\/1620713382.png\" alt=\"Xerostomia Treatment Market, Epidemiology, Emerging Therapies and Key Companies Working in the Domain During the Study Period (2018-30) in the 7MM\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Xerostomia Market <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Xerostomia Report from DelveInsight provides an in-depth understanding of Xerostomia, historical and forecasted epidemiology, and Xerostomia market dynamics in the US, EU5 (Germany, Spain, Italy, France, and the United Kingdom), as well as Japan.\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/34c54f0af94cf8f782deec1160ec76f1.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/xerostomia-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Xerostomia Report<\/a> from DelveInsight provides an in-depth understanding of Xerostomia, historical and forecasted epidemiology, and Xerostomia market dynamics in the US, EU5 (Germany, Spain, Italy, France, and the United Kingdom), as well as Japan.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Highlights from the Xerostomia Market Repor<\/strong>t<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">According to Hahnel et al. (2014), the prevalence of Xerostomia was <strong>16 percent<\/strong> (patients with XI scores 10) and hyposalivation was <strong>31 percent<\/strong> (patients with induced salivary flow rate 0.7 ml\/min).<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">According to Rech et al findings, the prevalence of Xerostomia, low induced salivary flow rate, and low at rest salivary flow rate were <strong>338 (38.8%), 494 (56.6%), and 320 (36.7%),<\/strong> respectively.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Emerging therapies in the Xerostomia market are <strong>LBS020<\/strong> (Lubris BioPharma), <strong>AAV-AQP1<\/strong> (MeiraGTx), and others.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Major companies involved in Xerostomia are <strong>Lubris BioPharma, MeiraGTx,<\/strong> among others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">Request sample page @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/xerostomia-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Xerostomia Market<\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Xerostomia market report covers existing clinical practices, new drugs, individual therapies&#8217; market share, and current and forecasted Xerostomia market sizes in the 7MM (the United States, the EU5, Germany, Italy, Spain, and France), and Japan.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Xerostomia: Disease Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Xerostomia,<\/strong> defined as defined as dry mouth, &nbsp;is caused by insufficient salivary secretion as a result of irregular salivary gland activity, which is referred to as &#8220;actual&#8221; Xerostomia; however, most patients with Xerostomia do not have objective symptoms of hyposalivation. Oral dryness despite normal salivary gland function is referred to as &#8220;symptomatic&#8221; Xerostomia or &#8220;pseudo&#8221; Xerostomia.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Xerostomia Epidemiology Segmentation<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Xerostomia Total Prevalent Cases<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Xerostomia Gender-Specific Prevalent Cases<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Xerostomia Age-Specific Prevalent Cases<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Xerostomia Diagnosed and Treatable Cases<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Xerostomia Treatment Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Current treatment options for Xerostomia are:<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Topical Medications<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pilocarpine and Cevimeline<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Sprays<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Salivary Stimulants and Substitutes<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Xerostomia Market<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The demand of Xerostomia market will expand throughout the forecast period as new therapies like LBS020 and AAV-AQP1 by the major players like Lubris BioPharma and MeiraGTx are introduced and the patient pool grows.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">To learn more visit, <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/blog\/?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Xerostomia Market Size<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Xerostomia Pipeline Therapies and Key Companies<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">LBS020: Lubris BioPharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">AAV-AQP1: MeiraGTx<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table style=\"height: 408px; width: 384px;\">\n<colgroup>\n<col width=\"100\" \/>\n<col width=\"524\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\">1.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Report Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">2.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Executive Summary<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">3.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Xerostomia Market Overview at a Glance<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">4.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Disease Background and Overview: Xerostomia<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">5.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Xerostomia: Case Reports<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">6.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Xerostomia: Epidemiology Methodology<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">7.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Xerostomia: Epidemiology and Patient Population<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">8.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Xerostomia: Country-Wise Epidemiology<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">9.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Xerostomia: Treatments &amp; Medical Practices<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">10.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Xerostomia: Marketed Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">11.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Xerostomia: Emerging Therapies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">12<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Xerostomia Market Size<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">13.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">7MM Xerostomia: Country-Wise Market Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">14.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Xerostomia: Market Drivers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">15.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Xerostomia: Market Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">16.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">SWOT Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">17.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Xerostomia: Market Access and Reimbursement<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">18.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Appendix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">19.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Report Methodology<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">20.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">DelveInsight Capabilities<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">21.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Disclaimer<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">22.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">Get in touch with our Business executive @&nbsp;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/consulting?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Xerostomia Market Insights<\/a><\/strong>&nbsp;to know more&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/erosive-esophagitis-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Erosive Esophagitis Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&#8217;s &#8220;Erosive Esophagitis (EE) &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Erosive Esophagitis (EE) , historical and forecasted epidemiology as well as the Erosive Esophagitis (EE) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Sandeep Joshi<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=xerostomia-treatment-market-epidemiology-emerging-therapies-and-key-companies-working-in-the-domain-during-the-study-period-201830-in-the-7mm\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=xerostomia-treatment-market-epidemiology-emerging-therapies-and-key-companies-working-in-the-domain-during-the-study-period-201830-in-the-7mm\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Xerostomia Market The Xerostomia Report from DelveInsight provides an in-depth understanding of Xerostomia, historical and forecasted epidemiology, and Xerostomia market dynamics in the US, EU5 (Germany, Spain, Italy, France, and the United Kingdom), as well as Japan. The Xerostomia Report &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/xerostomia-treatment-market-epidemiology-emerging-therapies-and-key-companies-working-in-the-domain-during-the-study-period-201830-in-the-7mm_542767.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,420,403,404],"tags":[],"class_list":["post-542767","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542767","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=542767"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542767\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=542767"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=542767"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=542767"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}